TAFINLAR (dabrafenib mesylate)
ANTINEOPLASTIC - BRAF KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+5
Novartis Pharmaceuticals
Drug class
Antineoplastic - BRAF Kinase Inhibitors
Antineoplastic BRAF kinase inhibitors are a targeted drug class that selectively bind to and inhibit mutated forms of the BRAF serine/threonine protein kinase, most notably the constitutively active BRAF V600E and V600K variants. Read more about Antineoplastic - BRAF Kinase Inhibitors
5 drugs in this class 4 manufacturers
Drugs in Antineoplastic - BRAF Kinase Inhibitors
BRAFTOVI (encorafenib)
ORAL TREATMENTS FOR NON-SMALL CELL LUNG CANCER · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+3
ARRAY/PFIZER
OJEMDA (tovorafenib)
ANTINEOPLASTIC - BRAF KINASE INHIBITORS · LOW GRADE GLIOMA WITH BRAF FUSION OR MUTATION
DAY ONE BIOPHAR
OJEMDA (tovorafenib)
ANTINEOPLASTIC - BRAF KINASE INHIBITORS · LOW GRADE GLIOMA WITH BRAF FUSION OR MUTATION
DAY ONE BIOPHAR
TAFINLAR (dabrafenib mesylate)
ANTINEOPLASTIC - BRAF KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+5
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - BRAF Kinase Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic BRAF kinase inhibitors are a targeted drug class that selectively bind to and inhibit mutated forms of the BRAF serine/threonine protein kinase, most notably the constitutively active BRAF V600E and V600K variants.
By interrupting hyperactive signaling through the mitogen-activated protein kinase (MAPK/ERK) pathway, these agents suppress downstream cellular proliferation and induce apoptosis in dependent malignant cells.
Clinically, members of this class—including dabrafenib, encorafenib, and vemurafenib—are predominantly utilized, often in combination with MEK inhibitors, to treat advanced or metastatic melanoma, BRAF V600E–mutated metastatic colorectal cancer, BRAF-mutated non-small cell lung cancer, and select other BRAF-positive solid tumors.
-
fda.gov
Antineoplastic BRAF kinase inhibitors are a targeted drug class that selectively bind to and inhibit mutated forms of the BRAF serine/threonine protein kinase, most notably the constitutively active BRAF V600E and V600K variants
-
nih.gov
Antineoplastic BRAF kinase inhibitors are a targeted drug class that selectively bind to and inhibit mutated forms of the BRAF serine/threonine protein kinase, most notably the constitutively active BRAF V600E and V600K variants By interrupting hyperactive signaling through the mitogen-activated protein kinase (MAPK/ERK) pathway, these agents suppress downstream cellular proliferation and induce apoptosis in dependent malignant cells
-
cancer.gov
Antineoplastic BRAF kinase inhibitors are a targeted drug class that selectively bind to and inhibit mutated forms of the BRAF serine/threonine protein kinase, most notably the constitutively active BRAF V600E and V600K variants
-
patsnap.com
By interrupting hyperactive signaling through the mitogen-activated protein kinase (MAPK/ERK) pathway, these agents suppress downstream cellular proliferation and induce apoptosis in dependent malignant cells
-
fda.gov
Clinically, members of this class—including dabrafenib, encorafenib, and vemurafenib—are predominantly utilized, often in combination with MEK inhibitors, to treat advanced or metastatic melanoma, BRAF V600E–mutated metastatic colorectal cancer, BRAF-mutated non-small cell lung cancer, and select other BRAF-positive solid tumors
-
fda.gov
Clinically, members of this class—including dabrafenib, encorafenib, and vemurafenib—are predominantly utilized, often in combination with MEK inhibitors, to treat advanced or metastatic melanoma, BRAF V600E–mutated metastatic colorectal cancer, BRAF-mutated non-small cell lung cancer, and select other BRAF-positive solid tumors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.